(Q45737598)

English

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

scientific article published in May 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 December 2017

0 references

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis (English)

1 reference

Europe PubMed Central

15 December 2017

0 references

liver cirrhosis

0 references

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George Papatheodoridis

1

1 reference

Europe PubMed Central

15 December 2017

author name string

Papadimitropoulos VC

2

1 reference

Europe PubMed Central

15 December 2017

Hadziyannis SJ

3

1 reference

Europe PubMed Central

15 December 2017

language of work or name

0 references

publication date

1 May 2001

1 reference

Europe PubMed Central

15 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

15 December 2017

15

1 reference

Europe PubMed Central

15 December 2017

689-698

1 reference

Europe PubMed Central

15 December 2017

5

1 reference

Europe PubMed Central

15 December 2017

Natural history of hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

HCV-associated liver cancer without cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Risk factors and prevention of hepatocellular carcinoma in HCV infection.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Therapy of hepatitis C: patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Effects of interferon therapy in "non responder" patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00979.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2001.00979.X

1 reference

Europe PubMed Central

15 December 2017

release_k2bywrwrnfabnfzdvkhpboqp2i

1 reference

https://api.fatcat.wiki/v0/release/k2bywrwrnfabnfzdvkhpboqp2i

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45737598&oldid=2079841780"